What is HC Wainwright’s Forecast for MIST FY2028 Earnings?

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) – Investment analysts at HC Wainwright cut their FY2028 earnings estimates for shares of Milestone Pharmaceuticals in a report issued on Monday, March 17th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings per share of $0.43 for the year, down from their prior forecast of $0.46. HC Wainwright has a “Buy” rating and a $25.00 price objective on the stock. The consensus estimate for Milestone Pharmaceuticals’ current full-year earnings is ($0.62) per share. HC Wainwright also issued estimates for Milestone Pharmaceuticals’ FY2029 earnings at $1.81 EPS.

Milestone Pharmaceuticals Stock Down 2.0 %

MIST stock opened at $1.95 on Wednesday. The firm has a market cap of $104.04 million, a PE ratio of -2.41 and a beta of 1.83. The company has a debt-to-equity ratio of 2.18, a quick ratio of 15.40 and a current ratio of 15.40. The firm’s 50 day moving average price is $2.02 and its 200-day moving average price is $1.81. Milestone Pharmaceuticals has a one year low of $1.12 and a one year high of $2.75.

Institutional Trading of Milestone Pharmaceuticals

Institutional investors have recently made changes to their positions in the company. Jones Financial Companies Lllp raised its position in shares of Milestone Pharmaceuticals by 1,000.0% during the 4th quarter. Jones Financial Companies Lllp now owns 11,000 shares of the company’s stock valued at $26,000 after buying an additional 10,000 shares during the period. National Bank of Canada FI raised its position in shares of Milestone Pharmaceuticals by 163.4% during the 4th quarter. National Bank of Canada FI now owns 18,700 shares of the company’s stock valued at $44,000 after buying an additional 11,600 shares during the period. PVG Asset Management Corp purchased a new stake in shares of Milestone Pharmaceuticals during the 3rd quarter valued at approximately $46,000. Atria Investments Inc raised its position in shares of Milestone Pharmaceuticals by 44.4% during the 3rd quarter. Atria Investments Inc now owns 40,421 shares of the company’s stock valued at $61,000 after buying an additional 12,430 shares during the period. Finally, Cubist Systematic Strategies LLC purchased a new stake in shares of Milestone Pharmaceuticals during the 4th quarter valued at approximately $73,000. Hedge funds and other institutional investors own 86.18% of the company’s stock.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.